Category Archives: Biotechnology

Dr S Balasubramanya, BTFS Coordinator and Dr Mittur N Jagadish, Head-BioTech Facilitation Cell, KBITS, Government of Karnataka

Karnataka state has remained one of the major investment destinations in the biotech industry. Currently, the State of Karnataka contributes around 35 per cent of the Indian biotechnology sector. The state government has established Biotechnology Bio-Innovation Centre at Bengaluru Helix.

Theme-based biotech parks are at various stages of implementation in Bidar, Dharwad, Mangaluru and Mysuru. The state has already in place, multi-sector start-up policy with various industry specific incentives and ease of doing business measures to stimulate growth of industry in Karnataka.

Life Sciences Sector Skill Development Council (LSSSDC) has estimated life sciences industry which includes biotechnology industry to employ 1.5-1.6 million people by 2020. The sector is expected to see a possible supply gap upwards of 0.3-0.4 million, with the highest gap in the manufacturing segment.

The majority of full-time employees are distributed between marketing and manufacturing, and a limited number in R&D and other functions. Approximately, 40 per cent job roles are clustered at entry/junior level; 35 per cent at mid-level and 20 per cent at senior levels in the industry.

The junior and entry level positions that make up 40 per cent of the job roles requires attributes such as technical proficiency in laboratories, subject knowledge (basic and superior), high learning aptitude and thinking and questioning ability as key skills. Need is also felt for skill and capability building in Quality, IP and Regulatory aspects. Biotechnology industry in India is growing conservatively at 10 - 15 per cent and is said to be adding 15 to 20 per cent workforce to existing 50,000 jobs. The entry level jobs are 5 per cent of the 15 - 20 per cent workforce added each year.

Continue reading here:
Karnataka's biotechnology finishing school programme, five years on - BSI bureau (press release)

BENGALURU: For all Bioscience graduates pursuing BE, BTech, BSc, MSc, MTech and PhD courses, there is good news for their career. The department of Biotechnology at Sir M Visvesvaraya Institute of Tecnology (MVIT) is organising a three day national seminar on Entrepreneurial Opportunities in Biotechnology from March 23 - 25 at its campus. The seminar that is also open to inquisitive parents, energetic alumni, enthusiastic faculty and industry experts is expected to alleviate the many concerns of graduates and their parents regarding their future prospects and career development. HG Nagendra, professor and head of the Biotechnology department, said: "The focus of education is to not only train the students in curriculum defined skillsets but also to guide them towards realising their higher aspirations." The seminar includes invited plenary talks by subject experts, panel discussions, industry-academia interactive sessions, poster sessions, project idea presentations, several stalls and displays. Cash awards will be awarded to those with best presentations and networking at the seminar.

Continued here:
MVIT organises three-day national seminar on Biotechnology - Times of India

StockNewsJournal

Lookout for Price Target? EP Energy Corporation (EPE), Puma ... StockNewsJournal EP Energy Corporation (NYSE:EPE) plunged -4.92% with the closing price of $4.06. The overall volume in the last trading session was 953.56 thousand shares. Puma Biotechnology Inc (PBYI) Plunges 9.45% on March 21Equities.com ADAGE CAPITAL PARTNERS GP, LLC is the biggest holder of Puma Biotechnology, Inc. (NASDAQ:PBYI)Post Analyst Bullish Target Of Puma Biotechnology Inc (NYSE:PBYI) At $89Stock Observer Petro Global News 24 -Herald KS -The Oracle Examiner all 22 news articles »

See the rest here:
Lookout for Price Target? EP Energy Corporation (EPE), Puma ... - StockNewsJournal

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today released the list of speakers for plenary programs at the2017 World Congress on Industrial Biotechnology. The sessions will feature executives from the biofuels, household and personal care, and airline industries who will discuss technology breakthroughs, business partnerships and sustainability initiatives. The worlds largest industrial biotechnology event will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Qubec, Canada.

Brent Erickson, Executive Vice President, Industrial and Environmental at BIO, stated, The Plenary Program for the 2017 World Congress will cover several novel topics that are emerging within the industry. Panelists will provide an overview of the current state of biobased food ingredients, flavorings, and personal care products and where market trends are headed in the future. Additionally, industry representatives and trade reporters will discuss how to meaningfully communicate about the biobased economy.

Some highlighted Plenary Sessions include:

Biotech and the Future of Food Ingredients, Flavorings, and Personal Care Monday, July 24, 2017 3:45 pm - 5:00pm

Speakers:

Second Generation Biofuels Poised for Big Wins Tuesday, July 25, 2017 8:30 am - 10:00am

Moderator:Jim Lane, Editor and Publisher, The Digest Speakers:

Effectively Communicating the Benefits of Industrial Biotechnology Tuesday, July 25, 2017 11:45 am 1:30 pm

Moderator:Rebecca Coons, Senior Editor, Chemical Week, IHS Chemical Speakers:

All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentarymedia registrationis available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

For more information on the conference please visithttp://www.bio.org/worldcongress. For assistance, please contactworldcongress@bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces theBIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.BIOtechNOWis BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter.Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO-Europe Spring Conference March 20-22, 2017 Barcelona, Spain

BIO IP Counsels Committee Conference March 27-29, 2017 Newport Beach, CA

BIO International Convention June 19-22, 2017 San Diego, CA

BIO World Congress on Industrial Biotechnology July 23 - 26, 2017 Montral, Canada

Read the original post:
BIO Announces Plenary Sessions for 2017 World Congress on ... - Business Wire (press release)

Biotechnology has emerged as one of the most forward-looking fields of science in recent decades, and a large number of nations have set their sights on it as a long-term development pillar, given its wide range of applications and the leapfrogging of current information technology, which allows to further exploit its potential.

Biotechnology has already proven to be an option for growth in multiple economic sectors, finding applications of high importance in sectors such as pharmaceuticals, food, veterinary, cosmetic, environmental, agricultural, energy, among others, which make it an opportunity for those developing countries in search of a boost for the progress of their economies.

It is then in biotechnology that a country like Colombia, which occupies the second place after Brazil in world biodiversity, with around 10% of the fauna and flora of the planet, can find possibilities of great impact for its economic growth and technological development. However, it is not a simple challenge if one takes into account the little investment that, unfortunately, is destined for R&D in the country. For example, according to World Bank data for the year 2014, Colombia allocated about 0.2% of GDP for this purpose, an amount significantly lower than the world average of about 2%, and much lower than the number one country in this regard, South Korea, which investment in R&D is above 4% of GDP.

In this manner, the government, academics and companies must work together to transform this enormous biodiversity into a factory of knowledge and innovation that translates into solutions to both local and global problems, which in the long term will allow to narrow the economic-technological gap between Colombia and the most developed countries in the world.

Thus, in the commitment to research in general as a driving force for development, and in particular concerning the emerging biotechnology, intellectual property plays a decisive role for its progress; this is due to the fact that tools for the protection of inventions, such as patents, greatly influence the decision of companies to invest or not their capital in a particular sector, and even more in biotechnology, which is undoubtedly one of those with highest cost in both R&D and product development and process design.

Hence, it is possible to evidence in different countries a closely related upward trend between R&D spending and the filing of patent applications, making them a clear indicator of a country's innovation and inventive step. By way of example, this is clearly visible when comparing the number of patent applications filed in Colombia and South Korea, using data provided by the World Bank in this regard for the same year mentioned above. In Colombia, in 2014, 260 patent applications were filed by residents and 1898 by non-residents; values much lower than those in South Korea where the numbers amount to 164073 patent applications filed by residents and 46219 by non-residents for the same year.

Therefore, it is necessary a vision change from the government of Colombia that promotes the injection of public and private capital in R&D, which is supported by an intellectual property system that provides adequate legal protection to the inventions and compensates the economic efforts made in innovation. Taking into account the characteristics of the country, Colombia has the potential to establish, as one of the pillars of its economy, its own biodiversity together with biotechnology; however, to this day, this latter is greatly underestimated.

In this sense, the challenge for Colombia in the coming years is to recognize and take advantage of the immense potential for scientific research that it possesses, especially in terms of biotechnology, in order to have in the future the ability to offer products and services with high standards of quality and added value, derived from a sustainable exploitation of its natural resources that goes hand in hand with policies ensuring the technical, legal and economic conditions conducive to its realization.

Read the original here:
Biodiversity, Biotechnology and Intellectual Property: their relevance for the development of Colombia - Lexology (registration)

By Crystal Kim

The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far,suggesting that investors may be getting defensiveand they arent alone.

Credit Suisse upgraded its rating on pharmaceuticals/biotechnology to Overweight from Market Weight on Tuesday. That said the Health Care Select Sector SPDR (XLV) is down 0.21% as of Tuesday afternoon.

Broad market valuations and heightened risk for a short-term correction led Chief U.S. Equity Strategist Lori Calvasina to boost defensive exposure. Whats not to like valuations are slightly more attractive in the large-cap space and reasonable in small-cap, earnings momentum is so low that it could go only go up, flows are signaling a turnaround, and there are virtually no concerns about so-called crowding risk. She notes:

In large cap, net buy ratings, mutual fund overweights, and hedge fund net exposure have all been slipping from the high end of their historical range. In small cap, our sell-side indicator is also elevated, while our mutual fund indicator is moving up, and our hedge fund indicator is falling toward past lows. Importantly, sell-side ratings have shown a significant correlation with relative performance in both small and large cap.

There are many ways to play this trade. On the pharmaceuticals side, big exchange-traded funds iShares US Pharmaceuticals (IHE), PowerShares Dynamic Pharmaceuticals (PJP), and VanEck Vectors Pharmaceutical (PPH) deserve a look. All three are fairly concentrated; the iShares ETF tracks an index of 40 stocks while the PowerShares and VanEck ETFs follow an index of 25 stocks. Still mega-cap Johnson & Johnson (JNJ) is a substantial holding in all three.

However, biotechnology ETFs might be the better bet. Calvasina says that its healthcare industry scorecard suggests that biotech and life sciences stocks are the source of the broader industry groups valuation appeal.

ConsideriShares Nasdaq Biotechnology (IBB) and the SPDR S&P Biotech (XBI). IBB has a bigger swath of the sector with 162 constituents in the index that it tracks, while XBI has 87. IBBs top holdings are inlarge-caps such as Celgene (CELG) and Gilead Sciences (GILD) whereas XBI tends to be invested in small-caps. Being in the large-cap space worked in IBBs favor today. It is down 1.61% compared to XBIs 3.23% decline. Note however that the iShares ETF charges a higher fee of 0.47%. XBI charges 0.35%.

Read this article:
Biotechnology Gets A Shot In the Arm - Barron's (blog)

Allied Academies cordially invites all the participants across the globe from leading universities, clinical research institutions, diagnostic companies and all interested to share their research experiences in the Annual Biotechnology Congress during August 17-18, 2017 in Toronto, Canada with the theme of New Scientific Developments in Biotechnology of Modern Era.

Track 1:Biochemistry & Molecular Biotechnology

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment. Molecular biotechnology results from the convergence of many areas of research, such as molecular biology, microbiology, biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product.

The key drivers for molecular biology enzymes, kits and reagents market are the rising R&D expenditure by the pharmaceutical and biotech companies, and increasing public funding for life science research. The World Health Organization estimates that the total aged population may rise from 605 million in 2000 (11% of the global population) to 2 billion by 2050, accounting for 22% of the global population.

Track 2:Animal biotechnology

It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment. Animal biotechnology is the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to develop microorganisms for specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).

Track 3:Biomedicine Engineering

Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technology and polymerase chain retort which employ genes and DNA molecules to make a diagnosis diseases and put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

This field seeks to close the gap between engineering and medicine. It combines the design and problem solving skills of engineering with medical and biological sciences to advance health care treatment, including diagnosis, monitoring and therapy. Prominent biomedical engineering applications include the development of biocompatibleprostheses, various diagnostic and therapeutic medical devices ranging from clinical equipment to micro-implants, common imaging equipment such as MRIs and EEGs, regenerative tissue growth, pharmaceutical drugs and therapeutic biological.

Track 4:Agricultural Biotechnology

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includes plant breeding to raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques as Marker Assisted Breeding, which increases the effectiveness of conventional breeding.

Track 5:Food Processing & Technology

Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus like bacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins and anti-nutritional elements present naturally in food.

Track 6:Industrial Biotechnology

Industrial biotechnology is the application of biotechnology for industrial purposes, including industrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. Industrial Biotechnologyoffers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.

Track 7: Pharmaceutical Biotechnology

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs.Pharmaceutical Biotechnologyis an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs,diagnosticagents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes inhealthcarepractices and a significant contribution to the development of national economy.Biopharmaceuticalsconsists of large biological molecules which areproteins. They target the underlying mechanisms and pathways of a disease or ailment; it is a relatively young industry. They can deal with targets in humans that are not accessible with traditional medicines.

Track 8:Environmental biotechnology

Biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one tries to harness biological process for commercial uses and exploitation. The development, use and regulation of biological systems for remediation of contaminated environments and for environment-friendly processes (green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food, and nutrients in a synergistically integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".

Track 9:Genetic & Tissue Engineering

One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or 'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another.

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, or semisynthetic tissue and organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results include tissue-engineered bone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Track 10:Nano Biotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Track 11:Bioinformatics

Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of new molecular targets for drug discovery.

Track 12:Biotechnology investments and Biotechnology Grants

Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any.Biotechnology products arise from successful biotech companies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creating revolutionary products and tools that impact the lives of potentially millions of people are one of the fundamental reasons why all entrepreneurs start biotechnology companies.

Originally posted here:
Biotechnology 2017 | Biotechnology Congress | Canada ...

SAN GABRIEL, California, March 20, 2017 /PRNewswire/ --

ChineseInvestors.com (CIIX) ('CIIX' or the 'Company'), the premier financial information website for Chinese-speaking investors, today announces that it has established and registered XiBiDi Biotechnology Co., Ltd. in the Pudong Free-Trade Area in Shanghai, with registered capital requirements of $1.45 million USD over the next 10 years. XiBiDi Biotechnology will focus on the online and offline sales of health products including hemp-derived CBD (cannabidiol) oil, as well as hemp-based food and beverages. Notably, the Chinese character 'XiBiDi' is homophonic to 'CBD' in English.

"I am delighted about the establishment and registration of our new hemp company," says CIIX founder and CEO, Warren Wang. "XiBiDi Biotechnology is strategically located in the Pudong Free-Trade Area of Shanghai, China, where we have the opportunity to reach a consumer base of nearly 1.4 billion people. We believe that this large population affords XiBiDi an outstanding opportunity to be the provider of choice for natural hemp products."

XiBiDi Biotechnology will be the operator of CIIX's recently launched CBD online store, http://www.ChineseCBDoil.com, which will primarily focus on selling, where legal, hemp-based CBD nutrient and health products to Chinese-speaking customers worldwide through the online retail process. CIIX is also in preparations to open a retail store based in the predominantly Chinese community of San Gabriel, California.

The establishment of XiBiDi Biotechnology supplements these ventures as well as the company's broader mission to develop its presence in the hemp industry. In addition to retail and direct sales, the company will focus on the legal import of hemp-based (but not CBD oil products) health products in China - a population increasingly interested in the health benefits of hemp and CBD oil - and the export of hemp food and beverages to the United States, Canada and Europe.

"As the aging population in China increases, Chinese people are paying more attention to their health; thus, we believe that the development of the health industry has a very bright future. CIIX is very excited to be the world's first U.S. publicly traded company promoting hemp-based CBD health products and hemp foods that will help Chinese people improve their overall health. In addition, being located in the Pudong Free-Trade Area provides great convenience for the company's future import and export business as China enacts various measures to support the development of the Pudong Free-Trade Area," concludes Wang.

XiBiDi Biotechnology is registered as a wholly foreign enterprise and the registration is expected to be completed by the end of March.

About ChineseInvestors.com (CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational-related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based CBD health products via its new website: http://www.ChineseCBDoil.com.

For more information visit http://www.ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds:https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-looking Statement

Our discussion may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading 'Risk Factors'.

Contact: ChineseInvestors.com, Inc. 227 W. Valley Blvd, #208 A, San Gabriel, CA 91776

Investor Relations: Alan Klitenic +1-214-636-2548

Corporate Communications: NetworkNewsWire (NNW) New York, New York http://www.NetworkNewsWire.com 212-418-1217 Office Editor@NetworkNewsWire.com

Original post:
ChineseInvestors.com Launches XiBiDi Biotechnology to Reach China's 1.4 Billion Consumer Base - Yahoo Finance

"For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development services and GMP manufacturing of a broad portfolio of Antibody:Drug Conjugate (ADC) and Protein:Drug Conjugate (PDC) projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody:Peptide Conjugates, Antibody:Dye Conjugates, PEGylated proteins, and other bioconjugates including Biobetters," said Muctarr Sesay, Ph.D., Chief Scientific Officer at Goodwin Biotechnology. "Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of bioconjugates. When including our experience in manufacturing vaccines for use in early- and late-stage clinical trials, we found the Minneapolis Medical Research Foundation project to be highly intriguing."

"This is not an unusual approach for us when we initiate a project because we collaborate with many of our clients in the early stages of proof of concept/development by empirically recommending the appropriate processes to create a viable ADC or PDC candidate," Dr. Sesay continued. "We then blend that with a solutions-oriented approach to help our clients overcome significant challenges to ensure that the process for their candidate is robust, compliant, economical, and scalable."

"We are proud to help advance the treatment for this growing public health concern because we're confident in the expertise that our highly skilled scientists have developed in the areas of ADCs and PDCs, based on the successful work that we have done with over 400 client projects over the last 24 plus years," said Karl Pinto, Chief Executive Officer at Goodwin Biotechnology, Inc. "Our Bioconjugation capabilities complement our experience in successfully developing and manufacturing monoclonal antibodies, recombinant proteins, and vaccines through mammalian cell culture expression systems. So, as part of our Single Source Solution, Goodwin is uniquely qualified to partner with our clients to meet their needs by developing customized and flexible approaches for manufacturing antibodies and recombinant proteins, for example, and / or design the appropriate conjugation activities to cost effectively deliver their product candidates on time."

About the Minneapolis Medical Research Foundation

The Minneapolis Medical Research Foundation (MMRF) is a subsidiary of Hennepin Healthcare System, Inc., and operates as the research arm of Hennepin County Medical Center, an acute care research and teaching hospital in Minneapolis. MMRF is one of the largest nonprofit medical research organizations in Minnesota and consistently ranks in the top 10 percent of all institutions receiving research funding from the National Institutes of Health. To learn more, visit mmrf.org.

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a uniquely qualified CDMO that offers a Single Source Solution for our clients from cell line development (through our strategic partner), exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody:Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with numerous companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing in 2014.In addition, Goodwin Biotechnology was awarded 'Best in Sector: Biopharmaceutical Contract Development & Manufacturing' at Acquisition International magazine's 2015 Sector Performance Awards. Most recently, Goodwin Biotechnology received Global Health & Pharma's award for Best for BioProcess Development & cGMP Manufacturing in 2016, and Best in Mammalian Cell Culture Process Development & cGMP Manufacturing 2017. Click here to view the press releases!Additional information may be found at http://www.GoodwinBio.com.

Funding for this study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U01DA038876. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information, please contact:

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-minneapolis-medical-research-foundation-selects-goodwin-biotechnology-to-help-develop-and-manufacture-two-vaccines-to-treat-opioid-addiction-300426025.html

SOURCE Goodwin Biotechnology, Inc.

http://www.goodwinbio.com

Read the original:
The Minneapolis Medical Research Foundation Selects Goodwin Biotechnology to Help Develop and Manufacture ... - PR Newswire (press release)

SalvaRx Group is to invest $1m in Rift Biotherapeutics, a US biotechnology company that develops antibodies for use in oncology.

Following the investment, the company will hold about 30% stake in Rift, including new shares issued on the $90,000 loan already provided to Rift.

SalvaRx will have the option to invest up to $1.5m further if Rift achieves certain development targets, and will also have the option to buy all outstanding shares in Rift in exchange for new shares in SalvaRx.

Rift develops antibodies implicated in the inflammatory tumour and tumours infiltrating the immune cells microenvironment, and it recently won the Boehringer Ingelheim Innovation prize, which included additional laboratory space at BioLabs San Diego, an incubator for biotech start-ups.

SalvaRx chief executive Ian Walters said that the companys collaboration with Rift will provide it with financing to finish preclinical development and will also augment its team with SalvaRx's clinical development expertise.

Dr Miguel de los Rios, Rift's founder and chief executive, added: "Our novel non T-cell based immunotherapy targets offer complementary approaches to the current standard of care in immuno-oncology. We are researching the anti-tumour activity of our immunotherapy and potential utility with standard of care agents such as Opdivo, Keytruda, or Tecentriq.

Follow this link:
SalvaRx Group invests $1m in US biotechnology firm - DIGITALLOOK